Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Zbyšek Pavelek, Michal Novotný, Blanka Klímová, Marek Peterka, Pavel Potužník, Martina Kövári & Martin Vališ. (2021) DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment. Current Medical Research and Opinion 37:4, pages 589-596.
Read now
Read now
V Limmroth, J Reischl, B Mann, X Morosov, A Kokoschka, I Weller & T Schreiner. (2017) Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Preference and Adherence 11, pages 1325-1334.
Read now
Read now
Ivonne Weller, Anna Saake, Thomas Schreiner, Julika Vogelreuter & Nicolas Petroff. (2015) Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Preference and Adherence 9, pages 951-959.
Read now
Read now
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda & Kurt Marhardt. (2015) Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery 12:8, pages 1239-1250.
Read now
Read now
Luis Lizán, Marta Comellas, Silvia Paz, José Luis Poveda, Dennis M Meletiche & Carlos Polanco. (2014) Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Preference and Adherence 8, pages 1653-1664.
Read now
Read now
Florence Schwarzenbach, Michèle Dao Trong, Laurent Grange, Philippe E Laurent, Herve Abry, Joël Cotten & Corinne Granger. (2014) Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Preference and Adherence 8, pages 199-209.
Read now
Read now
Volker Limmroth & Kathrin Gerbershagen. (2014) Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Expert Opinion on Drug Delivery 11:12, pages 1969-1978.
Read now
Read now
Ad A Kaptein. (2013) Transjecting growth hormone: continuous nightmare or controlled nuisance? Evaluation of a new needle-free device. Patient Preference and Adherence 7, pages 703-708.
Read now
Read now
S. L. Shingler, P. Swinburn, S. Ali, R. Perard & A. J. Lloyd. (2013) A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis. Journal of Medical Economics 16:8, pages 1036-1042.
Read now
Read now
Janice L. Jones, Donna J. Scheidt, Ranbir S. Kaushal & Cathryn A. Carroll. (2013) Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Medical Economics 16:2, pages 213-220.
Read now
Read now
Alessandra Lugaresi. (2013)
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
. Expert Opinion on Drug Delivery 10:2, pages 273-283.
Read now
Read now
Articles from other publishers (17)
Kyle Berman, Simon Moss, Barry Holden-Theunissen, Nobuhiko Satou, Kenji Okada, Mark Latymer & Attila Antalfy. (2023) Design Development of the SMARTCLIC®/CLICWISE® Injection Device for Self-Administered Subcutaneous Therapies: Findings from Usability and Human Factor Studies. Advances in Therapy 40:7, pages 3070-3086.
Crossref
Crossref
Sergio Sauri-Suárez, Sandra Quiñones-Aguilar, Arturo Contreras-Marín, Erik Omar Ramiro-Guerrero, David Zúñiga-García, Leticia Salinas-Vázquez, Leonardo Llamas-López, Carolina León-Jiménez, Adriana García-Martell, Iliana González-Hernández, Erwin Chiquete & Silvia García. (2020) Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis. PLOS ONE 15:4, pages e0230959.
Crossref
Crossref
Fabrice Berna, Anja S. Göritz, Guillaume Behr & Steffen Moritz. (2020) Pill or needle? Determinants of the preference for long-acting injection over oral treatment in people facing chronic illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry 98, pages 109798.
Crossref
Crossref
Hannah G. Parish, Jacquelyn R. Morton & Julie C. Brown. (2019) A systematic review of epinephrine stability and sterility with storage in a syringe. Allergy, Asthma & Clinical Immunology 15:1.
Crossref
Crossref
Nicola Gelbmann, Alfred Zöchling, Alexander Pichotta, Torben Schmidt, Andrej Murányi, Thomas Ernegger, Katharina Pock & Jürgen Römisch. (2019) Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – Biochemical characterization, pathogen safety, and stability. Biologicals 60, pages 60-67.
Crossref
Crossref
Bernadette Porter. (2017) Commentary on “Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection” by Coghe et al.. Multiple Sclerosis Journal 24:2, pages 233-235.
Crossref
Crossref
Omar Khan, Peter Rieckmann, Alexey Boyko, Krzysztof Selmaj, Natalia Ashtamker, Mat D Davis, Scott Kolodny & Robert Zivadinov. (2016) Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Multiple Sclerosis Journal 23:6, pages 818-829.
Crossref
Crossref
Theodore R. Brown & Virginia I. Simnad. (2017) A Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications. International Journal of MS Care 19:2, pages 85-90.
Crossref
Crossref
Donald A. Barone, Barry A. Singer, Lubo Merkov, Mark Rametta & Gustavo Suarez. (2016) Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors. Neurology and Therapy 5:2, pages 155-167.
Crossref
Crossref
Diane V. Doughty, Corbin Z. Clawson, William Lambert & J. Anand Subramony. (2016) Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery. Journal of Pharmaceutical Sciences 105:7, pages 2105-2113.
Crossref
Crossref
Tjalf Ziemssen, Lauren Sylvester, Mark Rametta & Amy Perrin Ross. (2015) Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurology and Therapy 4:2, pages 125-136.
Crossref
Crossref
Jerry S. Wolinsky, T. Erik Borresen, Dennis W Dietrich, Daniel Wynn, Yulia Sidi, Joshua R. Steinerman, Volker Knappertz & Scott Kolodny. (2015) GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 4:4, pages 370-376.
Crossref
Crossref
Darrell J. Irvine, Xingfang Su & Brandon Kwong. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
48
.
Wai H. Lim, Doris Chan, Neil Boudville, Susan Pellicano, Helen Herson, Harry Moody, Brian Hutchison, Marianne Snedeker & Gursharan Dogra. (2012) Patients' Perceptions of Subcutaneous Delivery of Darbepoetin Alfa by Autoinjector Prefilled Pen Versus Prefilled Syringe: A Randomized, Crossover Study. Clinical Therapeutics 34:9, pages 1948-1953.
Crossref
Crossref
C. Lebrun. (2012) Les traitements de première ligne dans la sclérose en plaques. Pratique Neurologique - FMC 3:2, pages 73-89.
Crossref
Crossref
Agneta A Pagels & Britta Hylander. (2012) Anaemia management in chronic kidney disease patients. Journal of Renal Nursing 4:2, pages 81-85.
Crossref
Crossref
Virginia A DevonshireElisabetta Verdun di Cantogno. (2011) Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Therapeutic Delivery 2:11, pages 1455-1465.
Crossref
Crossref